Fortress Biotech Inc (FBIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $62.70M
Last updated: Nov 17, 2026 at 4:15 PM ET
Fortress Biotech Inc (FBIO) Statistics
Fortress Biotech (FBIO) has a market cap of $62.70M. It holds $126.61M more cash than debt, 201.93% of its market cap. It kept 177.32% of revenue as net income over the last 12 months.
Total Valuation
| Market Cap | $62.70M |
|---|---|
| Latest price (Nov 17, 2026) | $1.82 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 13, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.9x and 0.4x.
| P/E Ratio | 0.8x |
|---|---|
| Forward P/E | 0.7x |
| P/S Ratio | 0.9x |
| Forward P/S | 0.8x |
| P/B Ratio | 0.4x |
| P/TBV Ratio | 0.5x |
| P/OCF Ratio | 0.5x |
Price Statistics
The stock is down 30.53% over 52 weeks and trades 13.33% below its 50-day average.
| Beta (1Y) | 1.39 |
|---|---|
| 52-Week Change | -30.53% |
| 1-Month Change | -2.67% |
| 3-Month Change | -36.14% |
| 6-Month Change | -28.06% |
| 5-Year Change | -96.07% |
| 10-Year Change | -94.62% |
| Total Return (1Y) | -30.53% |
| Total Return (3Y CAGR) | -4.51% |
| Total Return (5Y CAGR) | -47.69% |
| Return vs SPY (1Y) | -43.39% |
| Max Drawdown (1Y) | -60.96% |
| Max Drawdown (3Y) | -64.27% |
| Sharpe Ratio (1Y) | -0.59 |
| Correlation with SPY (1Y) | 0.30 |
| 50-Day Average | $2.10 |
| 200-Day Average | $2.70 |
| 52-Week Range | $1.71 to $4.53 |
| RSI (14 Days) | 42.1 |
| Average Volume (20 Days) | 224.55K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.93x current liabilities, and total debt is 0.16x shareholder equity.
| Current Ratio | 2.93x |
|---|---|
| Quick Ratio | 2.82x |
| Debt / Equity | 0.16x |
| Debt / EBITDA | 0.18x |
| Interest Coverage | 14.28x |
Returns and Efficiency
Return on invested capital is 57.03% and return on equity is 77.57% over the last 12 months.
| Return on Equity (ROE) | 77.57% |
|---|---|
| Return on Assets (ROA) | 44.29% |
| Return on Invested Capital (ROIC) | 57.03% |
| Return on Capital Employed (ROCE) | 64.27% |
| ROA (5Y Average) | -61.56% |
| Asset Turnover | 0.30x |
| Inventory Turnover | 2.97x |
| Receivables Turnover | 1.66x |
| Cash Conversion Cycle | -474 days |
Taxes
Income tax took 5.18% of pretax income over the last 12 months.
| Income Tax (TTM) | $5.40M |
|---|---|
| Effective Tax Rate | 5.18% |
Scores
FBIO has an Altman Z-Score of -0.37, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -0.37 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $69.99M over the last 12 months is up 12.27% from the 12 months before.
| Revenue | $69.99M |
|---|---|
| Revenue Growth (YoY) | +12.27% |
| Gross Profit | $46.31M |
| Operating Income | -$29.56M |
| Pretax Income | $104.17M |
| Net Income | $124.11M |
| EBITDA | $140.57M |
| EBIT | $133.98M |
| Reported EPS (TTM) | $2.30 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 57.10% of the $280.21M in total assets.
| Cash and Equivalents | $152.19M |
|---|---|
| Total Debt | $25.58M |
| Net Cash | $126.61M |
| Net Cash Per Share | $3.75 |
| Working Capital | $138.60M |
| Shareholder Equity | $160.00M |
| Book Value Per Share | $4.74 |
| Tangible Book Value | $135.46M |
| Tangible Book Per Share | $4.01 |
| Total Assets | $280.21M |
| Total Liabilities | $103.19M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | $125.83M |
|---|---|
| FCF Per Share | $3.77 |
| Depreciation and Amortization | $6.60M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -42.23%.
| Gross Margin | 66.16% |
|---|---|
| Operating Margin | -42.23% |
| Pretax Margin | 148.83% |
| Net Margin | 177.32% |
| EBITDA Margin | 200.84% |
| EBIT Margin | 191.41% |
| Gross Margin (5Y Average) | 63.27% |
Growth
Revenue fell 5.83% a year over 3 years.
| Revenue Growth (3Y CAGR) | -5.83% |
|---|---|
| Revenue Growth (5Y CAGR) | +6.77% |
Dividends and Yields
FBIO does not pay a dividend.
| Earnings Yield | 125.00% |
|---|---|
| Buyback Yield | 91.11% |
Stock Splits
The last split was a 1-for-15 reverse split on Oct 10, 2023.
| Last Split Date | Oct 10, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:15 |
Peer Position
Against 7 similar companies, FBIO has the lowest P/S.
P/S RatioPeer median 12.3x
ROICPeer median -177.56%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -37.25%
| P/S Ratio | 0.9x vs 12.3x median |
|---|---|
| ROIC | 57.03% vs -177.56% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +12.27% vs -37.25% median |
Analyst Forecast
Consensus estimates put revenue growth at 33.80% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +33.80% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About FBIO
What is FBIO's market cap?
Fortress Biotech has a market cap of $62.70M.
What is FBIO's P/E ratio?
Fortress Biotech has a trailing P/E ratio of 0.8x and a forward P/E of 0.7x.
How many shares of FBIO are outstanding?
Fortress Biotech has 33.75M shares outstanding. The count is up 23.87% from a year earlier.
Does FBIO pay a dividend?
No. Fortress Biotech does not pay a dividend.
How much debt does FBIO have?
Fortress Biotech has $25.58M of total debt and $152.19M of cash and equivalents, a net cash position of $126.61M.
FBIO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors